Compare · AYTU vs ETON
AYTU vs ETON
Side-by-side comparison of Aytu BioPharma Inc. (AYTU) and Eton Pharmaceuticals Inc. (ETON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYTU and ETON operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ETON is the larger of the two at $1.84B, about 63.5x AYTU ($28.9M).
- ETON has been more active in the news (16 items in the past 4 weeks vs 11 for AYTU).
- ETON has more recent analyst coverage (7 ratings vs 3 for AYTU).
- Company
- Aytu BioPharma Inc.
- Eton Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $28.9M
- $1.84B
- 1M return
- +32.09%
- -
- 1Y return
- +32.09%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 11
- 16
- Recent ratings
- 3
- 7
Aytu BioPharma Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Eton Pharmaceuticals Inc.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Latest AYTU
- Aytu BioScience downgraded by Lake Street with a new price target
- SEC Form 10-Q filed by Aytu BioPharma Inc.
- SEC Form 425 filed by Aytu BioPharma Inc.
- Aytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results
- Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
- Aytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
- Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026
- FDA Approval for ZOLPIMIST issued to AYTU
Latest ETON
- Amendment: SEC Form SCHEDULE 13G/A filed by Eton Pharmaceuticals Inc.
- Chief Commercial Officer Erdogan-Trinkaus Ipek exercised 3,500 shares at a strike of $15.47 and sold $235,937 worth of shares (3,500 units at $67.41) (SEC Form 4)
- Director Casamento Charles J exercised 80,555 shares at a strike of $5.44 and sold $5,345,072 worth of shares (80,555 units at $66.35) (SEC Form 4)
- SEC Form 144 filed by Eton Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Eton Pharmaceuticals Inc.
- SEC Form 10-Q filed by Eton Pharmaceuticals Inc.
- Eton Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
- Eton Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability